New York City
Sunday, May 26, 2024
“THE CEO PUBLICATION owns both theceopublication.com and theceopublications.com websites"

Publication

Sandoz Bolsters Ophthalmic Portfolio with Acquisition of Cimerli from Coherus

A significant shift in the ophthalmic pharmaceuticals landscape is underway, with Swiss healthcare giant Sandoz announcing its planned acquisition of the Cimerli business from U.S. biopharmaceutical company Coherus BioSciences. This strategic move strengthens Sandoz’s position in the lucrative age-related macular degeneration (AMD) treatments market, marking a crucial step in its broader portfolio expansion strategy.

Cimerli is a biosimilar medication that closely mirrors the properties of Lucentis, a leading drug for treating AMD, a progressive eye disease affecting millions worldwide. The acquisition grants Sandoz access to a well-established, commercially successful product, enabling it to tap into an already-existing patient base and compete directly with Roche, the manufacturer of Lucentis.

Beyond immediate market access, the deal aligns with Sandoz’s commitment to biosimilar medicines. By leveraging its expertise in developing and commercializing these cost-effective alternatives to branded drugs, Sandoz aims to increase patient access to affordable AMD treatments, potentially impacting healthcare systems and public health outcomes positively.

Coherus, conversely, views the divestment as a strategic move to streamline its portfolio and focus on developing proprietary assets in other therapeutic areas. The sale of Cimerli offers Coherus financial resources to support these endeavors, potentially fueling its long-term growth trajectory.

While the transaction’s financial terms remain undisclosed, analysts anticipate a significant sum, reflecting the value of Cimerli and its market prospects. The deal is expected to close in the first half of 2024, subject to customary closing conditions and regulatory approvals.

The impending acquisition will likely have a ripple effect within the ophthalmic market. Increased competition, driven by Sandoz’s entry, could reduce treatment costs and benefit patients struggling with AMD. Additionally, the consolidation within the biosimilar space could pave the way for further mergers and acquisitions, potentially reshaping the competitive landscape.

Sandoz’s acquisition of Cimerli signifies a bold move, strategically bolstering its portfolio and positioning it for growth in the lucrative AMD market. Coherus, conversely, utilizes the divestment to refine its focus and fuel its pipeline of promising therapies. As the deal unfolds, industry stakeholders and healthcare providers will closely watch its impact on patient access, competition, and the broader ophthalmic landscape.

Get The Latest Updates

Subscribe To Our Weekly Newsletter

No spam, notifications only about new products, updates.
Receive the latest news

Request for online magazine

Join Us

Advertise with us

meteroid vecrtor
Receive the latest news

Contact Us